In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB: Will Cimzia Be Enough?

Executive Summary

Cimzia's success is critical for UCB--not least to justify its $2.7 billion Celltech acquisition. But Cimzia will also be a test-case for whether mid-cap pharma can compete in biologics, particularly as the new Medicare program rolls out.
Advertisement

Related Content

Best of the Blog: IN VIVO, May/June 2009
Best of the Blog: IN VIVO, May/June 2009
Can Amgen Find a New Engine?
Can Amgen Find a New Engine?
European Consolidation: Serious Competition for Big Pharma?
European Consolidation: Serious Competition for Big Pharma?
Bioteching UCB-and Maybe Mid-Sized Pharma, Too
Bioteching UCB-and Maybe Mid-Sized Pharma, Too

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel